TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05437575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: fentanyl citrate 10mcg/ml packaged in pre-filled syringe
Study: NCT05738005

Intervention type: OTHER
Group type: OTHER
Intervention: Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)
Description: Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
Study: NCT06194409

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography, Urine analysis , blood culture
Description: All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography, Urine analysis , blood culture
Description: All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography
Study: NCT04966143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY011
Description: Targeting CLDN 18.2 Car-T injection
Study: NCT06212479

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Scan
Description: Whole Body MRI Scan
Study: NCT05030896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive treatment and exercise therapy
Description: The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive treatment and exercise therapy
Description: The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
Study: NCT04075916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
Study: NCT05573477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1013 placebo
Description: Placebo matched to ATB-1013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1013 placebo
Description: Placebo matched to ATB-1013
Study: NCT05326412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
Study: NCT06180317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
Study: NCT04811560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleximenib
Description: Bleximenib is administered orally.
Study: NCT05335447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667 capsule
Description: On Day 1, participants will receive a single oral dose of GLPG3667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG3667 solution for infusion
Description: On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
Study: NCT06246734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hasbro Joy for All robot pet companion
Description: The robot pets are stuffed animals (dogs and cats) that have features that make them seem lifelike. For example, the animal toys turn their heads when petted, purr or make puppy sounds, feel warm, have a heartbeat, and go to sleep when they are ignored. They respond to attention and petting like a real pet. The robot pets do not collect information and do not require any maintenance, except a battery. Engagement with the device is at the discretion of participants.
Study: NCT05025865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given in capsule form to study participants.
Study: NCT06561438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20Mg Tab
Description: 20 mg oral vortioxetine tablet 2 hours before the procedure
Study: NCT06015659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zentalis
Description: Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
Study: NCT05335447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG3667 capsule
Description: On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
Study: NCT05346848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of darolutamide and EBRT
Description: Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD

Intervention type: DRUG
Group type: OTHER
Intervention: Association of ADT and EBRT
Description: Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Study: NCT06266299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2269
Description: KK2269 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2269
Description: KK2269 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: antineoplastic drug administered intravenously
Study: NCT05316571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 5-Minute Walking Bout Each Hour
Description: One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
Study: NCT04775173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study: NCT05316571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 15-Minute Standing Bout Each Hour
Description: One 15-minute standing break per hour throughout the 4-hour SB condition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour
Description: Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
Study: NCT04946084

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tympanocentesis
Description: When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Phalangeal Swab and Wash
Description: Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
Study: NCT05316571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uninterrupted Sitting
Description: No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
Study: NCT04946084

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Description: Venipuncture
Study: NCT06024473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+iVCT
Description: Transcranial Magnetic Stimulation and immersive virtual reality
Study: NCT04253626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Injection [Feraheme]
Description: 510mg intravenous ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 325mg oral ferrous sulfate
Study: NCT05999708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin will be administered.
Study: NCT05171413

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
Study: NCT04775173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study: NCT06420167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10mg orally once daily
Study: NCT05050097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be self-administered orally.
Study: NCT05293639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Field Ablation
Description: PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
Study: NCT06268873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat/dapagliflozin
Description: baxdrostat tablet~dapagliflozin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin in combination with placebo
Description: dapagliflozin tablet~placebo tablet
Study: NCT06212791

Intervention type: BEHAVIORAL
Intervention: Self- Report Evaluation-Duke Activity Status Index
Description: Complete the Self- Report Evaluation-Duke Activity Status Index

Intervention type: BEHAVIORAL
Intervention: Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire
Description: Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise test (CPET)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: Transthoracic echocardiogram at rest and immediately following peak exercise during CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory cardiac rhythm assessment
Description: Ambulatory cardiac rhythm assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
Study: NCT05180058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrapping + Breastmilk Group
Description: Interventions applied during orogastric tube insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrapping + Breastmilk Group
Description: Interventions applied during orogastric tube insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrapping + Breastmilk Group
Description: Interventions applied during orogastric tube insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrapping + Breastmilk Group
Description: Interventions applied during orogastric tube insertion
Study: NCT04717414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT05555160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC
Description: Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC
Description: Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
Study: NCT04833907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV-Olig001-ASPA
Description: Intracerebroventricular administration of a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
Study: NCT06081829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Subjects will take 2 tablets (500 mg total) orally once daily.
Study: NCT06650514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-103
Description: OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
Study: NCT05260320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Anesthetic Course from Premedication to Induction
Description: See information in intervention group description
Study: NCT05560646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OG-6219
Description: OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OG-6219
Description: OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OG-6219
Description: OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
Study: NCT06095115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally
Study: NCT06605079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex intervention
Description: A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: No complex intervention is established, just routine procedures.
Study: NCT06597994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber UI system
Description: Upgrade of Amber UI system recharge accessories and system firmware
Study: NCT06589024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
Study: NCT06571734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06589024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Access to sleep hygiene education materials
Study: NCT06655636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Assistance
Description: The device spring components will be tuned to produce an assistive supination torque on the forearm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Assistance
Description: The device spring components will be tuned to produce an assistive supination torque on the forearm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Sham (Slack Springs)
Description: The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
Study: NCT06571734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Given PO
Study: NCT04850261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG Injection
Description: Ovulation will be induced by subcutaneous hCG injection
Study: NCT06655636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Sham (Slack Springs)
Description: The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Anti-Assistance
Description: The device spring components will be tuned to produce a resistive supination torque on the forearm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Anti-Assistance
Description: The device spring components will be tuned to produce a resistive supination torque on the forearm.